Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study
This real-world study demonstrated that the combination of a PD-1 inhibitor and PARPi exhibited sustained antitumor activity with an acceptable safety profile in the fourth-line treatment of patients with mCRPC.
Authors
- Yinchi Zhang (ORCID: https://orcid.org/0009-0003-1751-5959)
- Hua Huang (ORCID: https://orcid.org/0000-0002-8936-3371)
- Zihao Liu (ORCID: https://orcid.org/0000-0003-4685-2228)
- Shen Zhang (ORCID: https://orcid.org/0009-0008-9222-4437)
- Yang Liu (ORCID: https://orcid.org/0000-0002-9284-1944)
- Yong Wang (ORCID: https://orcid.org/0000-0001-8518-6745)
- Yuan Shao
- Zhiqiang Fu (ORCID: https://orcid.org/0000-0003-4198-4539)
- Zeyuan Wang (ORCID: https://orcid.org/0000-0003-0186-1710)
Institutions
- Second Hospital of Tianjin Medical University (CN)
- Office of the Governor (US)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Current Urology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1097/cu9.0000000000000304
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00